Cigna (CI) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Cigna reported $67.13 billion in revenue for Q2 2025, an 11% year-over-year increase, with an EPS of $7.20 compared to $6.72 a year ago, exceeding Zacks Consensus Estimates [1] - The revenue surprise was +7.09% over the consensus estimate of $62.69 billion, while the EPS surprise was +0.84% over the consensus estimate of $7.14 [1] Financial Performance Metrics - Medical Care Ratio was 83.2%, matching the average estimate by analysts [4] - Total Medical Customers reached 18.05 million, surpassing the average estimate of 17.92 million [4] - U.S. Healthcare Medical Customers were 16.36 million, slightly above the estimate of 16.23 million [4] - International Health Medical Customers were 1.69 million, in line with the estimate [4] - Net investment income was $236 million, exceeding the average estimate of $219.84 million, but representing a year-over-year decline of 26.5% [4] - Pharmacy revenues were $53.65 billion, significantly above the estimate of $49.16 billion, reflecting a 19% year-over-year increase [4] - Revenues from Evernorth Health Services were $57.83 billion, exceeding the estimate of $54.43 billion, with a year-over-year increase of 16.7% [4] - Evernorth Health Services Pharmacy revenues were $53.99 billion, surpassing the estimate of $51.33 billion, with a year-over-year increase of 16.9% [4] - Cigna Healthcare Premiums revenues were $8.99 billion, slightly above the estimate of $8.87 billion, but showing a year-over-year decline of 21.5% [4] - Total Premiums revenues were $9.16 billion, exceeding the estimate of $8.7 billion, with a year-over-year decline of 20.1% [4] - Fees and Other revenues were $4.14 billion, above the estimate of $4.05 billion, reflecting a year-over-year increase of 13.4% [4] - Cigna Healthcare revenues were $10.8 billion, slightly above the estimate of $10.78 billion, but showing a year-over-year decline of 18.2% [4] Stock Performance - Cigna's shares have returned -7% over the past month, contrasting with the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]